A preclinical study in a murine model by Han et al. demonstrated that systemic HER2 CAR-T cell therapy was effective in treating HER2-positive GC and did not affect tissues expressing low levels of HER2, thus suggesting no on-target, off-tumor effect. The gene discussed is ERBB2; the disease is neoplasm.